Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SD-101 plus pembrolizumab for HNSCC

Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses an exciting trial of SD-101, a TLR9 agonist that is given via intratumor injection, with pembrolizumab for head and neck squamous cell carcinoma (NCT02521870). The study investigated this combination in two groups: patients who had never received a PD-1 inhibitor before, and PD-1 refractory patients. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.